micro-community-banner
 
  • Saved

3yr
Association Between Aluminum Exposure From Vaccines Before Age 24 Months and Persistent Asthma at Age 24 to 59 Months

Association Between Aluminum Exposure From Vaccines Before Age 24 Months and Persistent Asthma at Age 24 to 59 Months

Source : https://www.academicpedsjnl.net/article/S1876-2859(22)00417-X/fulltext

In a large observational study, a positive association was found between vaccine-related aluminum exposure and persistent asthma. While recognizing the small effect sizes identified and the potential for unmeasured confounding,...


Discussion: Among children with eczema, vaccine-associated aluminum was positively associated with persistent asthma (aHR 1.26 per 1 mg increase in aluminum, 95% CI 1.07, 1.49); a positive association was also detected among children without eczema (aHR 1.19, 95% CI 1.14, 1.25).

  • Saved

3yr
Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis

Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis

Source : https://www.ajmc.com/view/skin-biomarkers-found-to-predict-development-of-pediatric-atopic-dermatitis

Significant alterations were observed in lipid levels and other skin biomarkers for infants who later developed atopic dermatitis (AD) vs those who did not, according to study findings published recently...


Discussion: Between the 2 cohorts, significant alterations were observed for 4 lipid markers, with P levels shown to be significantly lower in children who developed AD vs children who did not (median 240 vs 540 pmol/mg; P

  • Saved

3yr
Reducing Costs in Atopic Dermatitis - PubMed

Reducing Costs in Atopic Dermatitis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36131640/

Reducing AD treatment costs requires consideration of prophylactic therapies, patient education, and should differ based on the severity of disease. A multifaceted approach to AD treatment reduces costs and healthcare...


Conclusion: Reducing AD treatment costs requires consideration of prophylactic therapies, patient education, and should differ based on the severity of disease. A multifaceted approach to AD treatment reduces costs and healthcare barriers.

  • Saved

3yr
Topical JAK Inhibitors for Atopic Dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.




  • How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?

  • In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?


  • 3yr
    Topical JAKs will play a significant role in treating AD patients of all severities because of their efficacy that appears to be substantially better than other non-steroid topicals like TCIs Show More
  • 3yr
    I don't think topical JAKs have been a game changer in mild to moderate AD - unfortunately in part because most insurance plans don't seem to cover them well without Show More

Show More Comments

  • Saved

3yr
Topical JAK Inhibitors for Atopic Dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.

Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.

  • How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?
  • In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?
  • 3yr
    Topical JAKs will play a significant role in treating AD patients of all severities because of their efficacy that appears to be substantially better than other non-steroid topicals like TCIs Show More
  • 3yr
    I don't think topical JAKs have been a game changer in mild to moderate AD - unfortunately in part because most insurance plans don't seem to cover them well without Show More

Show More Comments